Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | GRM5 | P41594 | 14/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30707869 | 0.80 | KCNH2 (0.67) | KCNH2GRM5CYP2D6CYP2C9PTGDR2 | |
| SCHEMBL4562631 | 0.80 | KCNH2 (0.67) | KCNH2GRM5CYP2D6CYP2C9PTGDR2 | |
| Charcoal, Activated SCHEMBL31286308 | 0.78 | KCNH2 (0.64) | KCNH2GRM5CYP2D6CYP2C9PTGDR2 | |
| SCHEMBL98355 | 0.76 | — | — | |
| SCHEMBL1431909 | 0.76 | CA12 (0.50) | GRM5CYP3A4 | |
| SCHEMBL19128668 | 0.76 | ALDH1A1 (0.45) | GRM5MAOB | |
| SCHEMBL138849 | 0.76 | GRM5 (0.50) | GRM5CYP3A4 | |
| SCHEMBL136855 | 0.76 | KCNH2 (0.45) | KCNH2GRM5CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL136854 | 0.76 | KCNH2 (0.45) | KCNH2GRM5CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL28577212 | 0.74 | GRM5 (0.46) | KCNH2GRM5CYP3A4CYP2C9PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113444090-A | Compound and application thereof | 北京鼎材科技有限公司 | 2021-09-28 | — | — | CN | disclosed |
| CN-107690426-B | Substituted cyclic amides as herbicides | FMC公司 | 2021-07-06 | — | — | CN | disclosed |
| US-10906873-B2 | Substituted cyclic amides as herbicides | FMC CORPORATION (US) | 2021-02-02 | — | — | US | disclosed |
| EP-3303287-B1 | SUBSTITUTED CYCLIC AMIDES AS HERBICIDES | FMC CORP (US) | 2020-12-16 | — | — | EP | disclosed |
| CN-107406461-B | Heterocyclic alkyne derivatives and their use as mGluR5 receptor modulators | 雷科尔达蒂爱尔兰有限公司 | 2020-03-13 | — | — | CN | disclosed |
| EP-3240792-B1 | HETEROCYCLYLALKYNE DERIVATIVES AND THEIR USE AS MODULATORS OF MGLUR5 RECEPTORS | RECORDATI IRELAND LTD (IE) | 2019-01-23 | — | — | EP | disclosed |
| US-20180141904-A1 | SUBSTITUTED CYCLIC AMIDES AS HERBICIDES | FMC CORPORATION | 2018-05-24 | — | — | US | disclosed |
| EP-3303287-A1 | SUBSTITUTED CYCLIC AMIDES AS HERBICIDES | E. I. du Pont de Nemours and Company (US) | 2018-04-11 | — | — | EP | disclosed |
| US-9889121-B2 | Heterocyclylalkyne derivatives and their use as modulators of mGluR5 receptors | RECORDATI IRELAND LTD. (IE) | 2018-02-13 | — | — | US | disclosed |
| EP-3240792-A1 | HETEROCYCLYLALKYNE DERIVATIVES AND THEIR USE AS MODULATORS OF MGLUR5 RECEPTORS | Recordati Ireland Limited (IE) | 2017-11-08 | — | — | EP | disclosed |
| US-20170182011-A1 | HETEROCYCLYLALKYNE DERIVATIVES AND THEIR USE AS MODULATORS OF MGLUR5 RECEPTORS | RECORDATI IRELAND LTD (IE) | 2017-06-29 | — | — | US | disclosed |
| US-9593127-B2 | Heterocyclylalkyne derivatives and their use as modulators of mGluR5 receptors | RECORDATI IRELAND LTD. (IE) | 2017-03-14 | — | — | US | disclosed |
| WO-2016196019-A1 | SUBSTITUTED CYCLIC AMIDES AS HERBICIDES | E I DU PONT DE NEMOURS AND COMPANY (US) | 2016-12-08 | — | — | WO | disclosed |
| WO-2016107865-A1 | HETEROCYCLYLALKYNE DERIVATIVES AND THEIR USE AS MODULATORS OF MGLUR5 RECEPTORS | RECORDATI IRELAND LIMITED (IE) | 2016-07-07 | — | — | WO | disclosed |
| US-20160185798-A1 | HETEROCYCLYLALKYNE DERIVATIVES AND THEIR USE AS MODULATORS OF mGluR5 RECEPTORS | RECORDATI IRELAND LTD. (IE) | 2016-06-30 | — | — | US | disclosed |
| EP-2590985-B1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | RECORDATI IRELAND LTD (IE) | 2014-05-14 | — | — | EP | disclosed |
| US-8580962-B2 | Spiroheterocyclic compounds as mGlu5 antagonists | RECORDATI IRELAND LTD. (IT) | 2013-11-12 | — | — | US | disclosed |
| EP-2590985-A1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | Recordati Ireland Limited (IE) | 2013-05-15 | — | — | EP | disclosed |
| US-20120059015-A1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | RECORDATI IRELAND LTD. (IT) | 2012-03-08 | — | — | US | disclosed |
| WO-2012004400-A1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170182011-A1 | HETEROCYCLYLALKYNE DERIVATIVES AND THEIR USE AS MODULATORS OF MGLUR5 RECEPTORS | GRM5, GRIK5, GRM1 | KCNH2 1483/4885GRM5 1/4885CYP3A4 4191/4885 |
| US-10906873-B2 | Substituted cyclic amides as herbicides | CHRM2, DDT, CYP1A1 | KCNH2 906/4885GRM5 2214/4885CYP3A4 157/4885 |
| US-20160185798-A1 | HETEROCYCLYLALKYNE DERIVATIVES AND THEIR USE AS MODULATORS OF mGluR5 RECEPTORS | GRM5, GRIK5, GRM1 | KCNH2 1483/4885GRM5 1/4885CYP3A4 4191/4885 |
| US-20120059015-A1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | GRM5, GPR65, GRIK5 | KCNH2 994/4885GRM5 1/4885CYP3A4 3928/4885 |
| US-20180141904-A1 | SUBSTITUTED CYCLIC AMIDES AS HERBICIDES | CHRM2, DDT, CYP1A1 | KCNH2 906/4885GRM5 2214/4885CYP3A4 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.